



**IABS Meeting on
High Pathogenicity Avian Influenza
Vaccination Strategies to Prevent and Control
HPAI: Removing Unnecessary Barriers for Usage**

October 25 – 26, 2022

**OIE Headquarter
Paris, France**

**SPONSORSHIP OPPORTUNITIES
DOCUMENTATION**

CONTENT

Objectives of the Meeting.....	Page 3
Organization.....	Page 4
Scientific Committee & Speakers.....	Page 5
Provisional Agenda.....	Page 6
Sponsorship levels and benefits.....	Page 8
About International Alliance for Biological Standardization.....	Page 9

OBJECTIVES OF THE MEETING

Since October 2020, H5Nx 2.3.4.4b lineage of HPAI has spread across Europe, Middle East, Africa and Asia and is a threat to spread into North America. The uncontrolled spread of these viruses through wild aquatic bird migration is of utmost concern and ongoing climate changes contribute to a wider seasonal migration pattern. In addition, the keeping of poultry in free range systems has reduced physical separation of poultry and wild birds increasing risk of HPAI introduction into poultry. Thus, maintaining avian influenza freedom in poultry and preventing zoonotic infections are an increase challenge.

Vaccination can be a useful tool for prevention and control, but its use is prohibited or severely restricted in many countries worldwide. Wider use of avian influenza vaccination would increase sustainable poultry production, improve animal welfare, reduce economic damage, reduce human infections, and contribute to consumers and animal welfare acceptance of control programs.

A harmonised vaccination strategy with updated vaccine strains and innovative vaccine technologies, combined with appropriate diagnostics, surveillance, and disease management, can offer a better approach than stamping-out alone.

This workshop is intended to discuss how to reduce barriers for broader use of vaccination in avian influenza prevention and control strategy.

The workshop will be an open-discussion forum with participation by a wide variety of stakeholders (OIE, WHO, OFFLU, FAO, WTO, governments, breeding companies, animal welfare, human health, consumers, retailers, scientists, etc).

ORGANISATION

Dates: October 25 – 26, 2022

Format: on-site meeting

Location: OIE Headquarters – Paris - France

Participants: Up to 200 attendees expected

Venue:

OIE
World Organization for Animal Health
12, rue de Prony
75017 Paris
France
<https://www.oie.int/>

Website of the meeting: <https://hpai-paris-2022.iabs.org/>

Organizing coordinator:

Madinina Cox
@: Madinina.cox@iabs.org
Ph: +33 (0)6 35 31 40 90

IABS
Rue Mina-Audemars 3
CH-1204 Geneva
Switzerland

For more information regarding IABS : <https://www.iabs.org/>

SCIENTIFIC COMMITTEE & SPEAKERS

Scientific Committee :

- David Swayne, USDA, USA - chair
- Sjaak de Wit, GD Deventer, European College of Poultry Veterinary Science, The Netherlands
- Gounalan Pavade, OIE, France
- Madhur Dhingra, FAO, Italy
- Sophie Von Dobschuetz / FAO, IT
- Richard Webby, WHO Collaborating Center for Influenza, USA
- Les Sims, consultant veterinarian in Asia, Australia
- Marisa Peyre, CIRAD, France
- Connie Schmellik-Sandage, USDA, USA
- Ian Brown, APHA+ OFFLU, UK
- David Zeman, AAVLD, USA
- Timm Harder, FLI, Germany

Organizing Committee:

- Carmen Jungbäck, IABS-EU, Germany
- Rick Hill, IABS, USA
- Olivier Espeisse, CEVA, France

PROVISIONAL AGENDA

TUESDAY 25 OCTOBER, 2022

Session 1: Introduction to the meeting including objectives and expected outputs/outcomes

Session 2: Preventive vaccination in places where virus is not endemic in poultry and maintaining freedom from infection in poultry is the goal

- Focused presentations:
 - Factors that inhibit usage of preventive vaccination and ways to overcome them
 - The current OIE Avian Influenza Code Chapter and national requirements on vaccine usage
 - Vaccine technologies and availability, and what limits commercial availability of efficacious vaccines
 - Appropriate surveillance systems for vaccinated and non-vaccinated poultry populations
 - Public health considerations when contemplating avian influenza vaccination of poultry
- Facilitated Panel Discussion of a hypothetical situation of high risk for HPAI introduction into a country free from HPAI with the outcome of developing a sensible vaccination program for high-risk commercial poultry populations, including type(s) of vaccines to use, triggers for vaccination, surveillance and monitoring systems, trade considerations along with other constraints and concerns
- Break-out groups of participants to discuss and analyze the Facilitated Panel options presented and propose alternatives and/or solutions
- Presentations of Breakout Groups and final deliberations/summation by the panel

WEDNESDAY 26 OCTOBER, 2022

Session 3: Vaccination for outbreak control

- Presentations:
 - Vaccination as an aid to disease control and not stamping out alone, including examples and factors that impede vaccination in emergency control programs

- Trade issues relevant to emergency vaccination in places previously free from infection
- Vaccine options available and what might be developed
- Facilitated Panel Discussion of emergency vaccination program in a mega-layer farm in the face of an outbreak. The discussion to include consideration of emergency management planning (when/how to activate vaccination), how emergency vaccination would be administered, stockpiles, how to demonstrate that virus is no longer circulating, dealing with trade implications especially if “vaccinate to live” option is used, constraints to delivering vaccines, shifting away from mass destruction of poultry.
- Break-out groups of participants to discuss and analyze the Facilitated Panel options presented and propose alternatives and/or solutions
- Presentations of Breakout Groups and final deliberations/summation by the panel

Session 4: Vaccination in places where virus is endemic

- Facilitated Panel Discussion. Experiences from countries with endemic infection where vaccination has been used against HPAI – include panelists from China, Egypt, Mexico, Vietnam, Bangladesh, and Russia with experience using vaccines and one representative from an endemic country not using vaccines officially.
- Break-out groups of participants to discuss and analyze the Facilitated Panel options presented and propose alternatives and/or solutions
- Presentations of Breakout Groups and final deliberations/summation by the panel

Session 5: Summary Sessions, Conclusions and Recommendations

Session 6: Post-meeting: Produce 4 papers based on pre-meeting and *in meeting* discussions for publications

1. Vaccine technologies and availability:
2. Barriers to Vaccination and how to overcome them:
3. Devising sensible surveillance strategies:
4. Outcomes and Recommendations for the Workshop:

SPONSORSHIP LEVELS & BENEFITS



DIAMOND SPONSOR - €20,000

Logo recognition on the meeting website and on slides during the meeting
Direct link from the meeting website to your organization's website
Tabletop presentation
4 complimentary registrations



PLATINUM SPONSOR - €15,000

Logo recognition on the meeting website and on slides during the meeting
Direct link from the meeting website to your organization's website
Tabletop presentation
3 complimentary registrations



GOLD SPONSOR - €10,000

Logo recognition on the meeting website and on slides during the meeting
Direct link from the meeting website to your organization's website
2 complimentary registration



SILVER SPONSOR - €5,000

Logo recognition on the meeting website and on slides during the conference
Direct link from the meeting web site to your organization's website
1 complementary registration



BRONZE PARTNER - €3,000

Logo recognition on the meeting website and on slides during the meeting

International Alliance for Biological Standardization (IABS)

BACKGROUND

- The International Alliance for Biological Standardization (IABS) is an independent, non-profit scientific organization, located in Geneva (Switzerland).
- IABS was founded in Lyon, France, in 1955 by a group of independent experts who believed that such an organization could provide a forum where data could be discussed among scientists working in research, development, production, standardization and regulation of human and veterinary biological products with the ultimate aim of using sound scientific data to improve the quality of biological products and their regulation.
- The Alliance is:
 - headquartered in Geneva, Switzerland
 - recognized as a non-profit organization in Switzerland and USA.
 - officially recognized by WHO (World Health Organization) and by the OIE (Organisation Mondiale de la Santé Animale - World Organization for Animal Health) as an official non-governmental organization (NGO) that is in an official relationship with them.

MISSION

To promote consensus building on contemporary and emerging issues related to medical, scientific, and technological developments in human and veterinary biologicals, through interdisciplinary discussions, conferences, publications and partnerships

OBJECTIVES

- The objective of IABS-EU is to support the mission and projects of the International Alliance for Biological Standardization and to enhance its image and develop its outreach within the European Union.
- To provide a unique platform for discussion and the development of consensus positions on contemporary issues related to biologicals;
- To create an ongoing interface among leaders in clinical and basic research, biological product development, public health, manufacturing and regulation, by organizing scientific conferences and publishing reports of such meetings;
- To facilitate the establishment of international reference materials and the formulation of international guidance documents for biological substances used in human and veterinary medicine, through its conferences and publications;
- To promote uniform methods for establishing the international quality of biological products;
- To encourage research in connection with the characterization, standardization, quality, production, and clinical use of biological products.

website: www.iabs.org

e-mail: iabs@iabs.org